Last reviewed · How we verify
r-hGH
At a glance
| Generic name | r-hGH |
|---|---|
| Also known as | Saizen® |
| Sponsor | Merck KGaA, Darmstadt, Germany |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Human Models of Selective Insulin Resistance: Pancreatic Clamp (PHASE1)
- A Bioequivalence Study of Two Different PEG-rhGH Preparations (PHASE1)
- Safety and Efficacy Phase 3 Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children (PHASE3)
- A Study to Compare Eutropin Formulations in Healthy Volunteers for Bioavailability, Safety, and Tolerability (PHASE1)
- Long Term Follow up Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children (PHASE2)
- A Bioavailability Study of Two Different PEG-rhGH Preparations. (PHASE1)
- Development and Validation of a Self-assessment System Based on a Mobile App to Manage Adult Growth Hormone Deficiency (NA)
- A Bioequivalence Study of Two Different Processes of PEG-rhGH Preparations (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- r-hGH CI brief — competitive landscape report
- r-hGH updates RSS · CI watch RSS
- Merck KGaA, Darmstadt, Germany portfolio CI